Safety and Efficacy of Argatroban in the Management of Heparin-Induced Thrombocytopenia
Heparin-induced thrombocytopenia (HIT) is a life-threatening adverse reaction to heparin therapy that is characterized by thrombocytopenia and an increased risk of venous and arterial thrombosis. According to guidelines, in patients with strongly suspected or confirmed HIT all sources of heparin hav...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2011-01-01
|
| Series: | Clinical Medicine Insights: Blood Disorders |
| Online Access: | https://doi.org/10.4137/CMBD.S5118 |
| _version_ | 1811324777812459520 |
|---|---|
| author | Bernd Saugel Roland M. Schmid Wolfgang Huber |
| author_facet | Bernd Saugel Roland M. Schmid Wolfgang Huber |
| author_sort | Bernd Saugel |
| collection | DOAJ |
| description | Heparin-induced thrombocytopenia (HIT) is a life-threatening adverse reaction to heparin therapy that is characterized by thrombocytopenia and an increased risk of venous and arterial thrombosis. According to guidelines, in patients with strongly suspected or confirmed HIT all sources of heparin have to be discontinued and an alternative, nonheparin anticoagulant for HIT treatment must immediately be started. For both the prophylaxis of thrombembolic events in HIT and the treatment of HIT with thrombosis the direct thrombin inhibitor argatroban is approved in the United States. The objective of this review is to describe the mechanism of action and the pharmacokinetic profile of argatroban, to characterize argatroban regarding its safety and therapeutic efficacy and to discuss its place in therapy in HIT. |
| first_indexed | 2024-04-13T14:21:29Z |
| format | Article |
| id | doaj.art-0f29aa91abaf4fc9a63fe7242dbad7c7 |
| institution | Directory Open Access Journal |
| issn | 1179-545X |
| language | English |
| last_indexed | 2024-04-13T14:21:29Z |
| publishDate | 2011-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Clinical Medicine Insights: Blood Disorders |
| spelling | doaj.art-0f29aa91abaf4fc9a63fe7242dbad7c72022-12-22T02:43:27ZengSAGE PublishingClinical Medicine Insights: Blood Disorders1179-545X2011-01-01410.4137/CMBD.S5118Safety and Efficacy of Argatroban in the Management of Heparin-Induced ThrombocytopeniaBernd Saugel0Roland M. Schmid1Wolfgang Huber2II. Medizinische Klinik und Poliklinik. Klinikum rechts der Isar der Technischen Universität München, Ismaninger Strasse 22, D-81675 München, Germany.II. Medizinische Klinik und Poliklinik. Klinikum rechts der Isar der Technischen Universität München, Ismaninger Strasse 22, D-81675 München, Germany.II. Medizinische Klinik und Poliklinik. Klinikum rechts der Isar der Technischen Universität München, Ismaninger Strasse 22, D-81675 München, Germany.Heparin-induced thrombocytopenia (HIT) is a life-threatening adverse reaction to heparin therapy that is characterized by thrombocytopenia and an increased risk of venous and arterial thrombosis. According to guidelines, in patients with strongly suspected or confirmed HIT all sources of heparin have to be discontinued and an alternative, nonheparin anticoagulant for HIT treatment must immediately be started. For both the prophylaxis of thrombembolic events in HIT and the treatment of HIT with thrombosis the direct thrombin inhibitor argatroban is approved in the United States. The objective of this review is to describe the mechanism of action and the pharmacokinetic profile of argatroban, to characterize argatroban regarding its safety and therapeutic efficacy and to discuss its place in therapy in HIT.https://doi.org/10.4137/CMBD.S5118 |
| spellingShingle | Bernd Saugel Roland M. Schmid Wolfgang Huber Safety and Efficacy of Argatroban in the Management of Heparin-Induced Thrombocytopenia Clinical Medicine Insights: Blood Disorders |
| title | Safety and Efficacy of Argatroban in the Management of Heparin-Induced Thrombocytopenia |
| title_full | Safety and Efficacy of Argatroban in the Management of Heparin-Induced Thrombocytopenia |
| title_fullStr | Safety and Efficacy of Argatroban in the Management of Heparin-Induced Thrombocytopenia |
| title_full_unstemmed | Safety and Efficacy of Argatroban in the Management of Heparin-Induced Thrombocytopenia |
| title_short | Safety and Efficacy of Argatroban in the Management of Heparin-Induced Thrombocytopenia |
| title_sort | safety and efficacy of argatroban in the management of heparin induced thrombocytopenia |
| url | https://doi.org/10.4137/CMBD.S5118 |
| work_keys_str_mv | AT berndsaugel safetyandefficacyofargatrobaninthemanagementofheparininducedthrombocytopenia AT rolandmschmid safetyandefficacyofargatrobaninthemanagementofheparininducedthrombocytopenia AT wolfganghuber safetyandefficacyofargatrobaninthemanagementofheparininducedthrombocytopenia |